在多发性髓瘤中,KDM6A调节免疫反应基因
bioRxiv : the preprint server for biology
|February 26, 2024
概括
组织素脱甲基酶KDM6A通过调节多发性骨髓瘤中的免疫识别基因NLRC5和CIITA来抑制瘤. 在KDM6A缺乏的瘤中,HDAC3抑制剂可以恢复主要基因相容综合体 (MHC) 表达.
科学领域:
- 癌症生物学 癌症生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 免疫学 免疫学 免疫学
背景情况:
- KDM6A是一种多发性骨髓瘤 (MM) 的瘤抑制剂.
- KDM6A调节了参与免疫识别和细胞因子信号传递的基因.
- KDM6A直接影响NLRC5和CIITA的表达,这些基因是主要基因相容性复合体 (MHC) 基因的关键调节者.
研究的目的:
- 调查KDM6A在调节MM免疫识别中的作用.
- 探索KDM6A控制MHC基因表达的机制.
- 确定KDM6A缺乏MM的治疗策略.
主要方法:
- 创建的同源性MM细胞具有KDM6A破坏和内源性蛋白质标记.
- 进行了全基因组研究和染色质分析 (H3K27ac,H3K27me3).
- 分析了患者数据,并在细胞系模型中使用HDAC3抑制剂.
主要成果:
- KDM6A结合并激活NLRC5和CIITA,这对MHC表达至关重要.
- 在低KDM6A的MM中,NLRC5和CIITA的监管下调.
- KDM6A的损失减少了增强剂H3K27ac,增加了基因体H3K27me3,并减少了基因表达.
- 抑制HDAC3可以恢复KDM6A-null细胞中的MHC表达.
- 在小鼠中Kdm6a的损失增加了瘤的生长,并减少了T细胞的透.
结论:
- 通过调节NLRC5和CIITA,KDM6A对于MM的免疫识别至关重要.
- 通过KDM6A控制MHC表达的表观遗传修饰.
- HDAC3 抑制剂代表了一种潜在的治疗策略,用于增强KDM6A缺乏瘤的免疫性.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Master Transcription Regulators
6.9K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.9K


